# RheaVita

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rheavita

- Industry: Industrial Machinery
- Headquarters: Belgium
- Website: www.rheavita.com
- Total disclosed funding: $3M
- Latest round: Series A (Jun 1, 2021)
- Investors on record: 2

## About

Founded in 2018 and based in Belgium, RheaVita BV focuses on developing advanced lyophilisation technologies, particularly for the biopharmaceutical sector, enhancing manufacturing processes through innovative freeze-drying solutions.RheaVita BV specializes in advanced lyophilisation technologies, primarily targeting the biopharmaceutical sector. The company was founded in 2018 by Jos Corver and Thomas De Beer. It has received EUR 2.5 million in Series A funding, with the most recent deal occurring on June 2, 2021, co-led by Novalis Biotech and PMV - ParticipatieMaatschappij Vlaanderen NV. This total funding amount raised by the company is EUR 2.5 million.RheaVita offers advanced lyophilisation technologies, focusing on its RheaLyo™ platform, which includes the RheaLyo Mono freeze-dryer for research and development, and the GMP-compliant RheaLyo GMP-Flex series aimed at continuous freeze-drying systems. These technologies address limitations in traditional processes, enhancing product quality and operational efficiency. Target markets include Europe and North America, serving pharmaceutical companies, research institutions, and contract manufacturing organizations that require efficient freeze-drying solutions.In 2019, RheaVita generated revenue of EUR 335,377.5 with an EBITDA of EUR -427,595.7 reported for 2023. Revenue is derived from direct sales of RheaLyo freeze-drying equipment and services, primarily through B2B partnerships with pharmaceutical firms and research entities.Following the Series A funding of EUR 2.5 million raised on June 2, 2021, RheaVita plans to invest in building a good manufacturing practice (GMP) compliant freeze-drying production line and to accelerate the commercialization of its technology. The company aims to expand its product offerings and market reach, targeting new geographic regions and enhancing its capabilities to meet the growing demands of the biopharmaceutical sector.

## Funding rounds

- Series A, Jun 1, 2021, $3M — PMV, Novalis Biotech

## Investors

- PMV (https://capitalatlas.ai/funds/pmv) — Series A
- Novalis Biotech (https://capitalatlas.ai/funds/novalis-biotech) — Series A